• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human E3 ubiquitin-protein ligase RNF213 (RNF213), Truncated

ACP16998

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP16998 Target NameRNF213
FormLyophilized powderExpression SystemCustom Production. Please inquire and provide the desire expression system.
Protein LengthPartialPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ63HN8
Background Information
  • Uniprot Id

    Q63HN8

  • Target Species

    Human

  • Target Name

    RNF213

  • Target Full Name

    E3 ubiquitin-protein ligase RNF213

  • Target Function

    E3 ubiquitin-protein ligase involved in angiogenesis. Involved in the non-canonical Wnt signaling pathway in vascular development: acts by mediating ubiquitination and degradation of FLNA and NFATC2 downstream of RSPO3, leading to inhibit the non-canonical Wnt signaling pathway and promoting vessel regression. Also has ATPase activity.

  • Target Involvement

    Moyamoya disease 2 (MYMY2)

  • Target Subcellular Location

    Cytoplasm, cytosol.

  • Target Protein Families

    AAA ATPase family

  • Target Tissue Specificity

    Widely expressed (at protein level).

  • Target Synonyms

    ALK lymphoma oligomerization partner on chromosome 17; C17orf27; Chromosome 17 open reading frame 27; E3 ubiquitin-protein ligase RNF213; FLJ13051; KIAA1554; MGC46622; MGC9929; MYMY2; Mysterin; MYSTR; NET57; RING finger protein 213; RN213_HUMAN; RNF 213; RNF213

Inquire Recombinant Human E3 ubiquitin-protein ligase RNF213 (RNF213), Truncated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification